Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

24.18 +0.08 (+0.33%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: 
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 
From Beam Therapeutics
Via GlobeNewswire
Navigating 4 Analyst Ratings For Beam Therapeutics
Via Benzinga
Recap: Beam Therapeutics Q4 Earnings
Via Benzinga
MarketBeat Week in Review – 3/4 – 3/8
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
Via Benzinga
3 Biotech Stocks to Buy on the Dip: February 2024
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities 
Via InvestorPlace
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Beam Therapeutics
Via GlobeNewswire
Why Beam Therapeutics Stock Zoomed 17% Higher Today
JPMorgan Chase becomes the latest institution in the company's bull pen. 
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K
Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by 
Via Benzinga
Topics ETFs
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
Exposures Product Safety
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024. 
Via The Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.